🇺🇸 FDA
Patent

US 11981730

Anti-CXCL13 antibodies and methods of using the same

granted A61KA61K2039/505A61P

Quick answer

US patent 11981730 (Anti-CXCL13 antibodies and methods of using the same) held by VACCINEX, INC. expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61P, A61P1/04, A61P13/08